Last updated: 11/07/2018 16:55:53
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100mcg BID via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100mcg BID via the Diskhaler and Placebo in Subjects Aged 4 to 11 Years…
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100mcg BID via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100mcg BID via the Diskhaler and Placebo in Subjects Aged 4 to 11 Years…
Trial description: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100mcg BID via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100mcg BID via the Diskhaler and Placebo in Subjects Aged 4 to 11 Years…
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J. ALLERGY CLIN. IMMUNOL. 1998;102(1):32-38.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1996-30-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website